Mr. Cuong Do
Cuong Do is the founder and chairman of M6P Therapeutics, his third biotech startup. He previously founded Callidus Biopharma, which was acquired by Amicus Therapeutics for its drug for Pompe disease.
Do is currently the President and Chief Executive Officer of BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. He is an experienced life sciences executive who has served in various leadership roles at multiple global enterprises and publicly traded companies over the past 35 years. Do was President of Samsung Global Strategy Group where he helped to set the strategic direction for the company’s diverse business portfolio, including the growth of its biologics businesses. He was previously the Chief Strategy Officer for Merck (known as MSD outside the US), Lenovo and Tyco Electronics. He was a senior partner at McKinsey & Company, where he spent 17 years helping to build the company’s healthcare, high tech and corporate finance practices.
Do is also a passionate philanthropist, particularly in autism and education. He founded Profectum Foundation, which provides training and education for professionals and parents of children with autism or special needs. He founded Identifor to help autistic teenagers identify abilities and strengths to make the transition to adulthood. He currently or formerly served on the boards of Fulbright University Vietnam, The Tuck School of Business at Dartmouth, Autism Speaks, Celebrate the Children, Exceptional Minds, and Caring for Cambodia.
He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.